Phio Pharmaceuticals Corp.

Phio Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762. The second cohort had enrolled 4 patients who were diagnosed with cutaneous squamous cell carcinoma. At Day 36 (tumor excision), the first two patients who completed treatment showed a complete response (100% tumor clearance and a partial response 90% clearance), respectively. Pathology data assessing efficacy data on the remaining 2 patients is forthcoming. #Phio #RNAi #INTASYL

"Frontiers in Immunology" has published a paper by Phio in its December edition. The article presents preclinical proof-of-concept data for PH-762, an INTASYL compound designed to silence PD-1, is currently in clinical development for advanced cutaneous malignancies. Phio recently presented data from its second cohort in its on-going Phase 1b clinical trial showing one patient with cutaneous squamous cell carcinoma in the 2nd cohort achieved a complete response (100% tumor clearance) while a second patient with squamous cell carcinoma achieved a partial response (90% tumor clearance). Frontiers in Immunology is dedicated to propelling advancements in the field of Immunology. The Editor-in-Chief is Luigi Daniele Notarangelo, Director of the Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIH), and Senior Researcher at Boston Children’s Hospital, Harvard Medical School. #INTASYL #FrontiersInImmunology #Phio #RNAi

Phio is a finalist for the Technology Disruptor of the Year. The awards are part of Advanced Therapies Week 2025, a cell and gene conference that’s taking place January 20-23, 2025 in Dallas, Texas. According to the conference organizers, the award “celebrates exceptional contributions to the field of cell and gene therapy through technological innovation. It’s awarded to organizations and individuals who have significantly advanced their industry by effectively successfully implementing and utilizing new technologies.” Phio’s nomination focuses on its patented INTASYL® technology. #PHIO #RNAi #INTASYL #AdvancedTherapiesWeek

Batteries and biotech—two game changers! Join Patriot Battery Metals and Phio Pharmaceuticals Corp. as they present their latest innovations and updates. #RenmarkVNDRS Registration: PMET: https://ow.ly/oea550TOsFQ PHIO: https://ow.ly/g3j850TOsFK #PMET #Battery #metals #energy #PHIO #biotech #muscle #regenration

Phio has added a sixth clinical trial site for its Phase 1b study of PH-762. The San Diego site joins others in Florida, Washington, DC, Arizona, Pennsylvania and Ohio. #INTASYL #RNAi #PH762 #Immunooncology #Phio

Phio presented PH-762 clinical trial data (to date) showing one patient with cutaneous squamous cell carcinoma in the 2nd cohort achieved a complete response (100% tumor clearance) while a second patient with squamous cell carcinoma achieved a partial response (90% tumor clearance). The on-going clinical trial is designed to evaluate the safety and tolerability of intratumoral injection of PH-762 in patients with cutaneous squamous carcinoma, Merkel cell carcinoma and melanoma. #INTASYL #RNAi #siRNA #Phio #immunotherapy #immunooncology

Phio Director of Research and Program Management Melissa Maxwell is presenting tomorrow at the Advanced Therapies 2024 in Philadelphia. She'll be discussing INTASYL's applications in Adoptive Cell Therapy (ACT). #AdvancedTherapies2024 #INTASYL#Phio

Phio is presenting today at the Renmark Financial roadshow. Phio Pharmaceuticals welcomes stakeholders, investors, and other individual followers to register and attend this live event. REGISTER HERE: https://lnkd.in/eYGdTWSV To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.

Phio is presenting data today showcasing INTASYL’s role in helping T cells target and kill cancer cells. INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL, and CAR-T. INTASYL compounds, including PH-762, PH-804, PH-894 and PH-905, have been shown to improve the functionality and outcomes of Adoptive Cell Therapies (ACT) such as NK, TILs and CAR-T by increasing immune cell activation and expansion, facilitating higher yields of functional cells during ex vivo cell therapy manufacturing processes, optimizing therapeutic cell numbers. The data is being presented at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal. #INTASYL #RNAi #siRNA #Immunooncology #Phio

Phio CEO Bob Bitterman recently presented at the Renmark Financial Road Show in Chicago. The presentation can be streamed here (Chrome for best experience): #INTASYL #Phio #immunooncology #RNAi #siRNA